Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ADPKD (Autosomal Dominant Polycystic Kidney Disease) Clear all
Recruiting No phase listed Observational

A Prospective Observational Study of Foam Sclerotherapy .

NCT04111692
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney, Renal Cyst, Autosomal Dominant Polycystic Liver Disease, Hepatic Cyst
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 21, 2026, 4:30 PM EDT
Completed No phase listed Observational

Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease

NCT01114594
View directory record Official record
Conditions
Chronic Kidney Disease, Polycystic Kidney, Autosomal Dominant
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Jul 21, 2026, 4:30 PM EDT
Terminated Phase 3 Interventional Results available

Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat

NCT04705051
View directory record Official record
Conditions
Congenital Cystic Kidney Disease
Interventions
Venglustat GZ402671
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jul 21, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

Tolvaptan Extension Study in Participants With ADPKD

NCT01214421
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
38
States / cities
Mobile, Alabama • Peoria, Arizona • Tempe, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Jul 21, 2026, 4:30 PM EDT
Completed No phase listed Observational

Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).

NCT02173080
View directory record Official record
Conditions
Polycystic Liver Disease
Interventions
PLD-Q
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 21, 2026, 4:30 PM EDT
Completed Not applicable Interventional

A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)

NCT01810614
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
ADPKD Diet
Other
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Jul 21, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

NCT07022119
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 21, 2026, 4:30 PM EDT
Recruiting Phase 2 Interventional

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

NCT07161037
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
26
States / cities
Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 4:30 PM EDT
Completed Not applicable Interventional

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study

NCT00571909
View directory record Official record
Conditions
Kidney, Polycystic, Autosomal Dominant
Interventions
video thorascopic splanchnicectomy (VSPL)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Jul 21, 2026, 4:30 PM EDT
Terminated Phase 3 Interventional Results available

Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303

NCT05208866
View directory record Official record
Conditions
Polycystic Kidney Disease, Adult
Interventions
Lixivaptan
Drug
Lead sponsor
Palladio Biosciences
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Jul 21, 2026, 4:30 PM EDT
Active, not recruiting No phase listed Observational

Role of ROS and cAMP-PKA Biomarkers in ADPKD

NCT07217158
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
15 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 21, 2026, 4:30 PM EDT
Completed No phase listed Observational

Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease

NCT01039987
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years to 45 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Jul 21, 2026, 4:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

ADPKD Alterations in Hepatic Transporter Function

NCT03717883
View directory record Official record
Conditions
ADPKD, Autosomal Dominant Polycystic Kidney Disease, Renal Disease
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Jul 21, 2026, 4:30 PM EDT
Not yet recruiting Not applicable Interventional

Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT06786260
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Interventional Diet
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 21, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00428948
View directory record Official record
Conditions
Polycystic Kidney Disease, Autosomal Dominant
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
1,445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
30
States / cities
Mobile, Alabama • Riverside, California • Stanford, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 4:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00286156
View directory record Official record
Conditions
Polycystic Kidney Diseases
Interventions
Rapamune
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2015 · Synced Jul 21, 2026, 4:30 PM EDT
Recruiting No phase listed Observational

ADPKD Patient Registry

NCT04039061
View directory record Official record
Conditions
Polycystic Kidney Diseases
Interventions
Not listed
Lead sponsor
PKD Foundation
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 21, 2026, 4:30 PM EDT
Terminated Phase 3 Interventional Results available

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

NCT04152837
View directory record Official record
Conditions
Polycystic Kidney Disease, Adult, ADPKD
Interventions
Lixivaptan
Drug
Lead sponsor
Palladio Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Jul 21, 2026, 4:30 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Intrarenal Microvasculature in ADPKD

NCT05288998
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 21, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT02251275
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 21, 2026, 4:30 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234
View directory record Official record
Conditions
Kidney Disease
Interventions
GSK4771261, Placebo matching GSK4771261
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
25 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 21, 2026, 4:30 PM EDT
Completed No phase listed Observational

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT01430494
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Not listed
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
12 Years to 70 Years
Enrollment
3,409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
102
States / cities
Peoria, Arizona • Tempe, Arizona • Azusa, California + 89 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 21, 2026, 4:30 PM EDT
Terminated Not applicable Interventional Results available

Polycystic Liver Disease in Kidney Transplant

NCT00934791
View directory record Official record
Conditions
Polycystic Liver Disease
Interventions
Tacrolimus, Sirolimus, Mycophenolate Mofetil, Prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Jul 21, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

NCT01210560
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Tolvaptan MR, Tolvaptan IR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Jul 21, 2026, 4:30 PM EDT